Drugs / Donor-derived CMVpp65-specific T cells
Donor-derived CMVpp65-specific T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02985775 | Jan 2017 → Mar 2018 | cytomegalovirus infection | Peking University People's Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Donor-derived CMVpp65-specific T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02985775 ↗ |
| Action | Restore | “prophylactic or preemptive therapy with donor CMV-specific T cells can restore antiviral immunity and clear CMV viremia after transplantation” NCT02985775 ↗ |
| Modality | Cell therapy | “preemptive transfer of CMV-specific T cells at an early time point after allogeneic stem cell transplantation” NCT02985775 ↗ |